2820

Global X China Biotech ETF

Solactive China Biotech NR CNH

NAV as of

0.0000

4 Week: 52.50 - 55.70

52 Week: 51.74 - 79.32

Latest Closing Price

54.80

Premium / Discount

0

Expense Ratio

0.68%

Investment Objective

The ETF seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Solactive China Biotech Index NTR.

Main Fund Characteristics

Fund Manager:
Mirae Asset Global Investments (HK) Ltd
Asset Under Management:
533,847,347
Launch Date:
N.A
Asset Class:
Equity
Replication Method:
Physical-Full
Number of Holdings:
31
Trading Currency:
HKD
Style:
Large Blend
Region/Sector/Strategy:
N.A / N.A / N.A
Exchange:
HKEX

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-18.091.62-11.16
1 Day1.330.000.00
1 Week-0.693.08-0.22
1 Month4.746.600.72
3 Months-1.7912.29-0.15
6 Months-17.1217.24-0.99
1 Year-3.2530.27-0.11
2 Years-52.5346.23-1.14
3 Years0.000.000.00
5 Years0.000.000.00
10 Years0.000.000.00

Price History

-

Annual Performance Return

2013201420152016201720182019202020212022
Price (%) 0.00000.00000.00000.00000.00000.00000.000069.6975-19.6517-26.0911
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.00000.00000.00000.00000.00003.000082.000085.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
N.A

Portfolio Data

Total Number of Holdings: 31

Number of Bond Holdings: 0

Number of Equity Holdings: 30

Total Market Value: 533,847,347

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1Wuxi AppTec Co Ltd Class A10.7762718,851056,465,746
2WuXi Biologics (Cayman) Inc9.42571,296,264049,389,368
3Innovent Biologics Inc7.27861,076,258038,138,885
4Shanghai RAAS Blood Products Co Ltd Class A4.82133,666,600025,262,874
5Sino Biopharmaceutical Ltd4.23268,322,763022,178,123
6Beijing Tiantan Biological Products Corp Ltd Class3.6564771,600019,158,828
7China National Medicines Corp Ltd Class A3.2051512,800016,794,200
8Genscript Biotech Corp Class H2.9407853,876015,408,647
9Zai Lab Ltd ADR Repr 1 Shs2.848185,099014,923,535
10Akeso Inc Ordinary Shares2.8315434,738014,836,548

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant21.59
Large36.84
Medium16.68
Small2.94
Micro0.00

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

66.9270

Price/Book*

2.7275

Price/Sales*

10.6088

Price/Cash Flow*

41.0742

Dividend Yield*

0.6544

Growth Measures

Long-Term Earnings

13.4970

Historical Earnings

-3.4161

Sales Growth

9.1957

Cash-Flow Growth

-24.8147

Book-Value Growth

16.5811

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you